Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts still expect an approval and launch by year end of long-acting exenatide, now branded as Bydureon.
Advertisement

Related Content

Amylin Plans Cardiac Safety Study By The Book After Bydureon Rejection
Amylin Plans Cardiac Safety Study By The Book After Bydureon Rejection
Bydureon Goes Back To The QTc Drawing Board
Lilly Partners With Marcadia For Injectable Pens To Treat Hypoglycemia
GLP-1 Showdown Set For Fall: Bydureon Gets New October Review Deadline
Regulatory Updates, In Brief
Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
Lilly Slashes Revenue Forecasts For 2010 And 2011 Due To Health Care Reform
With Genentech Fully Integrated, Roche Lays Out Pipeline
Eyes On Byetta LAR: PDUFA Date Passes But Analysts Bet On 2010 Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS070345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel